MRKMEDIUM SIGNALFINANCIAL10-K

MRK's operating cash flow declined notably to $16.5B while the company increased capital investments and expanded its balance sheet, alongside new product developments including a subcutaneous formulation of Keytruda.

The 23% decline in operating cash flow suggests either timing differences in collections or underlying business pressures that warrant monitoring, particularly given MRK's established market position. However, the company's increased capital expenditures and balance sheet expansion indicate continued investment in growth initiatives, while new drug approvals and formulations like Keytruda SC demonstrate ongoing innovation efforts.

Comparing 2026-02-24 vs 2025-02-25View on EDGAR →
FINANCIAL ANALYSIS

MRK's financial profile shows mixed signals with operating cash flow declining meaningfully to $16.5B while the company increased capital spending by 22% to $4.1B, suggesting heightened investment activity. The balance sheet expanded robustly with total assets growing 17% to $136.9B and stockholders' equity increasing 14% to $52.6B, indicating solid financial positioning. R&D expenses decreased modestly by 12% to $15.8B, which combined with the cash flow decline, suggests potential shifts in the company's investment timing or operational dynamics.

FINANCIAL STATEMENT CHANGES
Operating Cash Flow
Cash Flow
-23.3%
$21.5B→$16.5B

Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.

Capital Expenditure
Cash Flow
+21.9%
$3.4B→$4.1B

Capex increased 21.9% — ongoing investment in capacity or infrastructure for future growth.

Total Assets
Balance Sheet
+16.9%
$117.1B→$136.9B

Asset base grew 16.9% — expansion through organic growth, acquisitions, or capital deployment.

Accounts Receivable
Balance Sheet
+14.6%
$10.3B→$11.8B

Receivables grew 14.6% — monitor days sales outstanding for collection efficiency.

Stockholders Equity
Balance Sheet
+13.6%
$46.3B→$52.6B

Equity base grew 13.6% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Current Assets
Balance Sheet
+12.2%
$38.8B→$43.5B

Current assets grew 12.2% — improving short-term liquidity or inventory/receivables build.

R&D Expense
P&L
-12%
$17.9B→$15.8B

R&D spending cut 12% — could signal cost discipline or concerning reduction in innovation investment.

LANGUAGE CHANGES
NEW — 2026-02-24
PRIOR — 2025-02-25
ADDED
Aggregate market value of Common Stock ($0.50 par value) held by non-affiliates on June 30, 2025 based on the closing price on June 30, 2025, the last business day of the registrant s most recently completed second fiscal quarter: approximately $ 198,051,000,000 .
Risk Factors 26 Cautionary Factors that May Affect Future Results 41 Item 1B.
Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) is a subcutaneously-administered fixed combination of pembrolizumab, an anti-PD-1 therapy, and berahyaluronidase alfa, which enhances dispersion and permeability to enable subcutaneous administration of pembrolizumab.
In some markets, it is approved as a new subcutaneous route of administration and new pharmaceutical form of Keytruda and is marketed as Keytruda SC .
Welireg (belzutifan) is a medication for the treatment of adult patients with certain von Hippel-Lindau (VHL) disease-associated tumors not requiring immediate surgery, for the treatment of adult patients with advanced RCC following a PD-1 or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (TKI) and for treatment of adult and pediatric patients 12 years and older with certain types of pheochromocytoma or paraganglioma.
Product Approvals Set forth below is a summary of significant product approvals received by the Company in 2025 and, to date, in 2026.
Product Date Approval Keytruda January 2025 China s National Medical Products Administration (NMPA) approval in combination with enfortumab vedotin, an antibody-drug conjugate (ADC), for the treatment of adults with locally advanced or metastatic urothelial carcinoma, based on the KEYNOTE-A39 trial that was conducted in collaboration with Seagen (now Pfizer Inc., Pfizer) and Astellas.
April 2025 European Commission (EC) approval in combination with pemetrexed and platinum chemotherapy for the first-line treatment of adult patients with unresectable non epithelioid malignant pleural mesothelioma, based on the IND.227/KEYNOTE-483 trial.
May 2025 Japan s Ministry of Health, Labor and Welfare (MHLW) approval in combination with trastuzumab and chemotherapy for the first-line treatment of patients with unresectable, advanced or recurrent HER2-positive gastric or GEJ adenocarcinoma, based on the KEYNOTE-811 trial.
May 2025 Japan s MHLW approval in combination with pemetrexed and platinum chemotherapy for unresectable, advanced or recurrent metastatic malignant pleural mesothelioma, based on the IND.227/KEYNOTE-483 trial.
REMOVED
Aggregate market value of Common Stock ($0.50 par value) held by non-affiliates on June 28, 2024 based on the closing price on June 28, 2024, the last business day of the registrant s most recently completed second fiscal quarter: approximately $ 313,799,000,000 .
Risk Factors 26 Cautionary Factors that May Affect Future Results 40 Item 1B.
Additionally, Keytruda is approved for patients with certain types of resectable NSCLC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.
Keytruda is also approved for certain patients with high-risk early stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.
Welireg (belzutifan) is a medication for the treatment of adult patients with certain von Hippel-Lindau (VHL) disease-associated tumors not requiring immediate surgery, and for the treatment of adult patients with advanced RCC following a PD-1 or PD-L1 inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor.
Hospital Acute Care Bridion (sugammadex), a medication for the reversal of two types of neuromuscular blocking agents used during surgery; Prevymis (letermovir) for the prophylaxis of cytomegalovirus (CMV) infection and disease, or of CMV disease, in certain high risk adult and pediatric recipients of an allogeneic hematopoietic stem cell transplant or of a kidney transplant, respectively; Dificid (fidaxomicin) for the treatment of C.
difficile -associated diarrhea; Zerbaxa (ceftolozane and tazobactam) for injection, a combination antibacterial and beta-lactamase inhibitor for the treatment of certain bacterial infections; and Noxafil (posaconazole), an antifungal agent for the prevention of certain invasive fungal infections.
Product Approvals Set forth below is a summary of significant product approvals received by the Company in 2024 and, to date, in 2025.
Food and Drug Administration (FDA) approval in combination with chemoradiotherapy for the treatment of patients with FIGO (International Federation of Gynecology and Obstetrics) 2014 Stage III-IVA cervical cancer, based on the KEYNOTE-A18 trial.
January 2024 FDA full approval for the treatment of patients with HCC secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1 containing regimen.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →